02157.HK
Lepu Biopharma Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 4.06
+3.44%Year over year
Reported trailing growth
- Revenue
- +39.4%
- EBITDA
- +256.8%
- EBIT
- +141.3%
- EPS
- +225.0%
- Free cash flow
- +18.2%
- Operating cash flow
- +16.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +288.2%
- EBITDA
- +43.4%
- EBIT
- +327.0%
- Net income
- +161.9%
- EPS
- +158.3%
- Free cash flow
- +67.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026